Search

Your search keyword '"Joshua, Anthony M."' showing total 908 results
Start Over Author "Joshua, Anthony M."
908 results on '"Joshua, Anthony M."'

1. A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation

Author

Thavaneswaran, Subotheni, Lin, Frank, Grady, John P., Espinoza, David, Huang, Min Li, Chinchen, Sarah, Sebastian, Lucille, Kansara, Maya, Mersiades, Tony, Lee, Chee Khoon, Desai, Jayesh, Grimison, Peter, Brown, Michael, Millward, Michael, Harrup, Rosemary, O’Byrne, Ken, Nagrial, Adnan, Craft, Paul, Simes, John, Joshua, Anthony M., and Thomas, David M.

Published
2024
Full Text
View/download PDF

2. Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors

Author

Dimitriou, Florentia, Orloff, Marlana M., Koch Hein, Erica C., Cheng, Phil F., Hughes, Isaac F., Simeone, Ester, Montazeri, Kamaneh, Grover, Piyush, Mehmi, Inderjit, Gerard, Camille L., Gaudy-Marqueste, Caroline, Grob, Jean-Jacques, Michielin, Olivier, Hamid, Omid, Long, Georgina V., Sullivan, Ryan, Kapiteijn, Ellen, Johnson, Douglas B., Ascierto, Paolo A., Joshua, Anthony M., Carvajal, Richard D., Butler, Marcus O., Hassel, Jessica C., and Dummer, Reinhard

Published
2025
Full Text
View/download PDF

5. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Author

Gillessen, Silke, Turco, Fabio, Davis, Ian D., Efstathiou, Jason A., Fizazi, Karim, James, Nicholas D., Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Zilli, Thomas, Agarwal, Neeraj, Antonarakis, Emmanuel S., Aparicio, Ana, Armstrong, Andrew J., Bastos, Diogo Assed, Attard, Gerhardt, Axcrona, Karol, Ayadi, Mouna, Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Bourlon, Maria T., Briganti, Alberto, Bulbul, Muhammad, Buttigliero, Consuelo, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Clarke, Caroline S., Clarke, Noel, de Bono, Johann S., De Santis, Maria, Duran, Ignacio, Efstathiou, Eleni, Ekeke, Onyeanunam N., El Nahas, Tamer I.H., Emmett, Louise, Fanti, Stefano, Fatiregun, Omolara A., Feng, Felix Y., Fong, Peter C.C., Fonteyne, Valerie, Fossati, Nicola, George, Daniel J., Gleave, Martin E., Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Hofman, Michael S., Hope, Thomas A., Horvath, Lisa G., Hussain, Maha H.A., Jereczek-Fossa, Barbara Alicja, Jones, Robert J., Joshua, Anthony M., Kanesvaran, Ravindren, Keizman, Daniel, Khauli, Raja B., Kramer, Gero, Loeb, Stacy, Mahal, Brandon A., Maluf, Fernando C., Mateo, Joaquin, Matheson, David, Matikainen, Mika P., McDermott, Ray, McKay, Rana R., Mehra, Niven, Merseburger, Axel S., Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Mutambirwa, Shingai B.A., Nguyen, Paul L., Oh, William K., Ost, Piet, O’Sullivan, Joe M., Padhani, Anwar R., Parker, Chris, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M, Rathkopf, Dana, Reiter, Robert E., Renard-Penna, Raphaele, Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sandhu, Shahneen, Sartor, Oliver A., Schaeffer, Edward, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona A., Soule, Howard R., Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Suzuki, Hiroyoshi, Taplin, Mary-Ellen, Thellenberg-Karlsson, Camilla, Tilki, Derya, Türkeri, Levent N., Uemura, Hiroji, Ürün, Yüksel, Vale, Claire L., Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, and Omlin, Aurelius

Published
2025
Full Text
View/download PDF

6. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

Author

Akhurst, T, Alipour, R, Au, L, Banks, P, Emerson, B, Hussain, N, Haskali, M, Lewin, J, Linklater, R, Kostos, L, Kashyap, R, Krishanth, P, Kong, G, Kumar, A, Murphy, D, Roselt, P, Sandhu, S, Scalzo, M, Tran, B, Wallace, R, Spain, L, Bourke, H, Milton, A, Russo, D, Bills, M, Chew, C, Hsieh, W, Crouch, B, Smyth, D, Pandelus, S, Lam, H, Gan, C, Goh, J, Scott, A, Hafeez, U, Ackermann, U, Young, K, Poon, A, Pathmaraj, K, Schembri, G, Roach, P, Bailey, D, Hung, T, Asad, A, Hagan, T, Watts, J, Campbell, E, Chua, W, Pal, A, Crumbaker, M, Nguyen, A, Yam, A, Chen, J, Ardolino, L, Kongrak, K, Ratnayake, L, Azad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, and Hofman, Michael S

Published
2024
Full Text
View/download PDF

8. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Author

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, Yip, Sonia, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S, McJannett, Margaret, Martin, Andrew James, Stockler, Martin R, and Davis, Ian D

Published
2024
Full Text
View/download PDF

9. The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors

Author

Chen, Sujun, Petricca, Jessica, Ye, Wenbin, Guan, Jiansheng, Zeng, Yong, Cheng, Nicholas, Gong, Linsey, Shen, Shu Yi, Hua, Junjie T, Crumbaker, Megan, Fraser, Michael, Liu, Stanley, Bratman, Scott V, van der Kwast, Theodorus, Pugh, Trevor, Joshua, Anthony M, De Carvalho, Daniel D, Chi, Kim N, Awadalla, Philip, Ji, Guoli, Feng, Felix, Wyatt, Alexander W, and He, Housheng Hansen

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Urologic Diseases, Human Genome, Prostate Cancer, Genetic Testing, Genetics, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Male, Humans, Epigenome, Cell-Free Nucleic Acids, Prostatic Neoplasms, Prostate, DNA Methylation
Abstract

Metastatic prostate cancer remains a major clinical challenge and metastatic lesions are highly heterogeneous and difficult to biopsy. Liquid biopsy provides opportunities to gain insights into the underlying biology. Here, using the highly sensitive enrichment-based sequencing technology, we provide analysis of 60 and 175 plasma DNA methylomes from patients with localized and metastatic prostate cancer, respectively. We show that the cell-free DNA methylome can capture variations beyond the tumor. A global hypermethylation in metastatic samples is observed, coupled with hypomethylation in the pericentromeric regions. Hypermethylation at the promoter of a glucocorticoid receptor gene NR3C1 is associated with a decreased immune signature. The cell-free DNA methylome is reflective of clinical outcomes and can distinguish different disease types with 0.989 prediction accuracy. Finally, we show the ability of predicting copy number alterations from the data, providing opportunities for joint genetic and epigenetic analysis on limited biological samples.

Published
2022

10. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.

Author

Hamid, Omid, Robert, Caroline, Daud, Adil, Carlino, Matteo S, Mitchell, Tara C, Hersey, Peter, Schachter, Jacob, Long, Georgina V, Hodi, F Stephen, Wolchok, Jedd D, Arance, Ana, Grob, Jean Jacques, Joshua, Anthony M, Weber, Jeffrey S, Mortier, Laurent, Jensen, Erin, Diede, Scott J, Moreno, Blanca Homet, and Ribas, Antoni

Subjects
Humans, Melanoma, Skin Neoplasms, Disease Progression, Neoplasm Staging, Prognosis, Drug Administration Schedule, Survival Rate, Patient Selection, Aged, Middle Aged, Female, Male, Antibodies, Monoclonal, Humanized, Clinical Decision-Making, Progression-Free Survival, Immune Checkpoint Inhibitors, PD-1, Pembrolizumab, Programmed death 1, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Cancer, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

ObjectivePatients with melanoma and early stable disease (SD) with pembrolizumab have unclear prognosis. We present post hoc analyses of long-term outcomes for patients with early SD, partial response (PR) or complete response (CR) with pembrolizumab.Patients and methodsPatients who received pembrolizumab in the KEYNOTE-001 and KEYNOTE-006 studies and had SD, PR or CR at weeks 12 or 24 were included.ResultsOf 294 patients in the week 12 analysis, 107 (36.4%) had SD at week 12, of whom 7 (6.5%) had a best overall response of CR, 43 (40.2%) had PR and 57 (53.3%) had SD. Forty-eight-month overall survival (OS) rates were 95.2%, 73.0% and 47.7%, respectively, for patients with CR, PR and SD at week 12. Similar results were observed in the 241 patients in the week 24 analysis. Forty-eight-month OS rates were 72.1% for patients with SD at week 12 followed by subsequent response and 75.0% for patients with PR at week 12 followed by no change in response or progression. Thirty-six-month and 48-month OS rates were 11.6% and not reached, respectively, for patients with SD at week 12 followed by progression before week 24.ConclusionsA substantial proportion of patients (46.7%) with early (week 12) SD with pembrolizumab achieved subsequent PR or CR. Patients with SD at week 12 and subsequent CR/PR had similar survival to those who maintained PR. In contrast, patients with SD at week 12 and subsequent progression had poor survival outcomes. These findings may guide treatment decisions for patients achieving early SD.Trial registrationClinicaltrials.gov: NCT01295827 (KEYNOTE-001); NCT01866319 (KEYNOTE-006).

Published
2021

14. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Author

Akhurst, Tim, Alipour, Ramin, Bailey, Dale, Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Crumbaker, Megan, Dhiantravan, Nattakorn, Hamid, Anis, Haskali, Mohammad, Hung, Terry, Kong, Grace, Lawrence, Nick, Lewin, Jeremy, McCarthy, Michael, Moodie, Kate, Murphy, Declan, Nguyen, Andrew, Pook, David, Ravi Kumar, Aravind, Roach, Paul, Roselt, Peter, Saghebi, Javad, Schembri, Geoff, Spain, Lavinia, Subramaniam, Shalini, Thang, Sue Ping, Thomas, Paul, Tran, Ben, Wallace, Roslyn, Yip, Sonia, Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R, Williams, Scott G, Martin, Andrew J, and Davis, Ian D

Published
2024
Full Text
View/download PDF

16. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

Author

Robert, Caroline, Hwu, Wen-Jen, Hamid, Omid, Ribas, Antoni, Weber, Jeffrey S, Daud, Adil I, Hodi, F Stephen, Wolchok, Jedd D, Mitchell, Tara C, Hersey, Peter, Dronca, Roxana, Joseph, Richard W, Boutros, Celine, Min, Le, Long, Georgina V, Schachter, Jacob, Puzanov, Igor, Dummer, Reinhard, Lin, Jianxin, Ibrahim, Nageatte, Diede, Scott J, Carlino, Matteo S, and Joshua, Anthony M

Subjects
Cancer, Vaccine Related, Immunization, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Clinical Trials as Topic, Drug-Related Side Effects and Adverse Reactions, Female, Follow-Up Studies, Humans, Male, Melanoma, Meta-Analysis as Topic, Middle Aged, Prognosis, Young Adult, Pembrolizumab, Advanced melanoma, Immune-related adverse events, Immune-checkpoint inhibitors, PD-1 inhibitors, Immunomodulating drugs, Corticosteroid use, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

ObjectiveLong-term safety of pembrolizumab in melanoma was analyzed in KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006.Patients and methodsAnalysis involved patients who received ≥1 pembrolizumab dose. Lead-time bias was addressed via landmark analyses in patients who were progression-free before day 147.ResultsAdverse events (AEs) were analyzed for 1567 patients (median follow-up, 42.4 months). Most AEs were mild/moderate; grade 3/4 treatment-related AEs occurred in 17.7% of patients. Two pembrolizumab-related deaths occurred. Any-grade immune-mediated AEs (imAEs) occurred in 23.0%, most commonly hypothyroidism (9.1%), pneumonitis (3.3%), and hyperthyroidism (3.0%); grade 3/4 imAEs occurred in 6.9% of patients. Most imAEs occurred within 16 weeks of treatment. In landmark analysis, patients who did (n = 79) versus did not (n = 384) develop imAEs had similar objective response rates (ORRs) (64.6% versus 63.0%); median time to response (TTR), 5.6 months for both; median duration of response (DOR), 20.0 versus 25.3 months; median progression-free survival (PFS), 17.0 versus 17.7 months; median overall survival (OS), not reached (NR) versus 43 months (p = 0.1104). Patients who did (n = 17) versus did not (n = 62) receive systemic corticosteroids had similar ORRs (70.6% vs. 62.9%) and median TTR (6.4 vs. 5.6 months) but numerically shorter median PFS (9.9 vs. 17.0 months); median DOR, 14.2 months versus NR; median OS, NR for both.ConclusionsThese results enhance the knowledge base for pembrolizumab in advanced melanoma, with no new toxicity signals after lengthy follow-up of a large population. In landmark analyses, pembrolizumab efficacy was similar regardless of imAEs or systemic corticosteroid use.Clinical trial registryNCT01295827, NCT01704287, NCT01866319.

Published
2021

19. Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302

Author

Wilson, Brooke E., Armstrong, Andrew J., de Bono, Johann, Sternberg, Cora N., Ryan, Charles J., Scher, Howard I., Smith, Matthew R., Rathkopf, Dana, Logothetis, Christopher J., Chi, Kim N., Jones, Robert J., Saad, Fred, De Porre, Peter, Tran, NamPhuong, Hu, Peter, Gillessen, Silke, Carles, Joan, Fizazi, Karim, and Joshua, Anthony M.

Published
2022
Full Text
View/download PDF

21. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

Author

Yu, Evan Y., Kolinsky, Michael P., Berry, William R., Retz, Margitta, Mourey, Loic, Piulats, Josep M., Appleman, Leonard J., Romano, Emanuela, Gravis, Gwenaelle, Gurney, Howard, Bögemann, Martin, Emmenegger, Urban, Joshua, Anthony M., Linch, Mark, Sridhar, Srikala, Conter, Henry J., Laguerre, Brigitte, Massard, Christophe, Li, Xin Tong, Schloss, Charles, Poehlein, Christian H., and de Bono, Johann S.

Published
2022
Full Text
View/download PDF

22. Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer.

Author

Rollin, Samuel P. G., Lawrence, Mitchell G., Joshua, Anthony M., and Selth, Luke A.

Subjects
ANDROGEN receptors, CASTRATION-resistant prostate cancer, PROSTATE cancer, TUMOR growth, ANTINEOPLASTIC agents
Abstract

Inhibiting the activity of the androgen receptor (AR) is the cornerstone treatment for advanced prostate cancer. AR-targeted therapies are highly effective in slowing disease progression but are not curative. Failure of these therapies results in a disease state termed castration-resistant prostate cancer, which is associated with significant patient morbidity and mortality. In most cases, resistance to AR-targeted therapies arises due to alterations that reactivate the AR signalling axis. Interestingly, it has long been recognised that potent activation of AR with supraphysiological levels of androgens can suppress prostate cancer growth in both preclinicalmodels and patients. This intriguing paradox, where both inhibition and activation of AR have anti-cancer effects, is nowbeing harnessed clinically in the formof bipolar androgen therapy (BAT). This review describes mechanisms underlying the tumour-suppressive functions of AR in the context of potent androgenic stimulation and discusses howourmaturing understanding of these processes is influencing the clinical deployment of BAT. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

23. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

Author

Parnis, Francis, Joshua, Anthony M., Horvath, Lisa G., Steer, Christopher, Marx, Gavin, Sandhu, Shahneen, Gurney, Howard, Ferguson, Thomas, Van Bruwaene, Siska, Luyten, Daisy, Schatteman, Peter, Lumen, Nicolaas, Dirix, Luc, Goeminne, Jean-Charles, Gil, Thierry, Seront, Emmanuel, Vulsteke, Christof, Kussumoto, Celio, Franke, Fabio A., Martinelli de Oliveira, Fabricio Augusto, Pereira de Santana Gomes, Andrea Juliana, Pinczowski, Hélio, Preto, Daniel D'Almeida, Zucca, Luis Eduardo, Borges, Giuliano Santos, Murad, Andre M., Saad, Fred, Chi, Kim N., Fradet, Yves, Fleshner, Neil E., Emmenegger, Urban, Brasso, Klaus, Fizazi, Karim, Culine, Stephane, Thiery-Vuillemin, Antoine, Joly, Florence, Fléchon, Aude, Hilgers, Werner, Eymard, Jean-Christophe, Borchiellini, Delphine, Barthélémy, Philippe, Berger, Raanan, Leibowitz-Amit, Raya, Mermershtain, Wilmosh, Rouvinov, Keren, Peer, Avivit, Kovel, Svetlana, Sella, Avishay, Lolkema, Martijn P., van den Eertwegh, Alfonsus J.M., Voortman, Johannes, Aarts, Maureen J., Gietema, Jourik A., Kim, Choung-Soo, Choi, Young-Deuk, Chung, Byung-Ha, Gafanov, Rustem A., Kopyltsov, Evgeniy, Usynin, Evgeny A., Carles, Joan, Mellado, Begoña, Maroto, José Pablo, García-Donás, Jesús, Rodríguez Moreno, Juan Francisco, Durán, Ignacio, Pérez-Valderrama, Begoña, Castro, Elena, Olmos, David, Méndez-Vidal, María José, Estellés, David Lorente, Sarrió, Regina Gironés, Muñoz-Langa, José, Herranz, Urbano Anido, Puente Vázquez, Javier, Castellanos, Enrique, Hellström, Martin, Widmark, Anders, Lissbrant, Ingela Franck, Jellvert, Åsa, Külich, Cecilia, Blom, René, Ståhl, Olof, Chiang, Po-Hui, Kang, Chih-Hsiung, Ou, Yen-Chuan, Wang, Shian-Shiang, Wu, Hsi-Chin, Lu, Yu-Chuan, Attard, Gerhardt, Khoo, Vincent, Bahl, Amit, Kellati, Prasad, Parikh, Omi, Srinivasan, Rajaguru, Lester, Jason F., Staffurth, John N., Cheng, Heather H., Efstathiou, Eleni, Pilié, Patrick G., George, Daniel J., Karsh, Lawrence I., Kelly, W. Kevin, Danila, Daniel C., Sieber, Paul R., Smith, Matthew R., Heath, Elisabeth I., Vaishampayan, Ulka N., Flaig, Thomas W., Emamekhoo, Hamid, Pinski, Jacek K., Kalebasty, Arash Rezazadeh, Maly, Joseph J., Moon, Helen, Smith, Matthew R, Scher, Howard I, Lara, Primo N, Jr, Yu, Evan Y, George, Daniel J, Chi, Kim N, Danila, Daniel C, Mason, Gary E, Espina, Byron M, Zhao, Xin, Urtishak, Karen A, Francis, Peter, and Lopez-Gitlitz, Angela

Published
2022
Full Text
View/download PDF

24. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Author

Joseph, Richard W, Elassaiss-Schaap, Jeroen, Kefford, Richard, Hwu, Wen-Jen, Wolchok, Jedd D, Joshua, Anthony M, Ribas, Antoni, Hodi, F Stephen, Hamid, Omid, Robert, Caroline, Daud, Adil, Dronca, Roxana, Hersey, Peter, Weber, Jeffrey S, Patnaik, Amita, de Alwis, Dinesh P, Perrone, Andrea, Zhang, Jin, Kang, S Peter, Ebbinghaus, Scot, Anderson, Keaven M, and Gangadhar, Tara C

Subjects
Cancer, Clinical Research, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose: The purpose of this study was to assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (NCT01295827).Experimental Design: BTS was quantified by adding the sum of the longest dimensions of all measurable baseline target lesions. BTS as a dichotomous and continuous variable was evaluated with other baseline factors using logistic regression for objective response rate (ORR) and Cox regression for overall survival (OS). Nominal P values with no multiplicity adjustment describe the strength of observed associations.Results: Per central review by RECIST v1.1, 583 of 655 patients had baseline measurable disease and were included in this post hoc analysis. Median BTS was 10.2 cm (range, 1-89.5). Larger median BTS was associated with Eastern Cooperative Oncology Group performance status 1, elevated lactate dehydrogenase (LDH), stage M1c disease, and liver metastases (with or without any other sites; all P ≤ 0.001). In univariate analyses, BTS below the median was associated with higher ORR (44% vs. 23%; P < 0.001) and improved OS (HR, 0.38; P < 0.001). In multivariate analyses, BTS below the median remained an independent prognostic marker of OS (P < 0.001) but not ORR. In 459 patients with available tumor programmed death ligand 1 (PD-L1) expression, BTS below the median and PD-L1-positive tumors were independently associated with higher ORR and longer OS.Conclusions: BTS is associated with many other baseline clinical factors but is also independently prognostic of survival in pembrolizumab-treated patients with advanced melanoma. Clin Cancer Res; 24(20); 4960-7. ©2018 AACR See related commentary by Warner and Postow, p. 4915.

Published
2018

25. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

Author

Mak, Blossom, Lin, Hui-Ming, Kwan, Edmond M., Fettke, Heidi, Tran, Ben, Davis, Ian D., Mahon, Kate, Stockler, Martin R., Briscoe, Karen, Marx, Gavin, Zhang, Alison, Crumbaker, Megan, Tan, Winston, Huynh, Kevin, Meikle, Thomas G., Mellett, Natalie A., Hoy, Andrew J., Du, Pan, Yu, Jianjun, Jia, Shidong, Joshua, Anthony M., Waugh, David J., Butler, Lisa M., Kohli, Manish, Meikle, Peter J., Azad, Arun A., and Horvath, Lisa G.

Published
2022
Full Text
View/download PDF

26. A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.

Author

Fleshner, Neil E., primary, Bernardino, Rui Miguel, additional, Lajkosz, Katherine, additional, Saad, Fred, additional, Izawa, Jonathan, additional, Drachenberg, Darrel, additional, Saranchuk, Jeff W., additional, Tanguay, Simon, additional, Rendon, Ricardo A., additional, Leveridge, Michael, additional, Shayegan, Bobby, additional, Fairey, Adrian, additional, Cockburn, Jessica Grace, additional, Berlin, Doron, additional, Hamilton, Robert James, additional, Sildva, Tiiu, additional, Breau, Rodney H., additional, Richard, Patrick O., additional, Klotz, Laurence, additional, and Joshua, Anthony M., additional

Published
2024
Full Text
View/download PDF

28. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

Author

Lin, Hui-Ming, Mak, Blossom, Yeung, Nicole, Huynh, Kevin, Meikle, Thomas G., Mellett, Natalie A., Kwan, Edmond M., Fettke, Heidi, Tran, Ben, Davis, Ian D., Mahon, Kate L., Zhang, Alison, Stockler, Martin R., Briscoe, Karen, Marx, Gavin, Crumbaker, Megan, Stricker, Phillip D., Du, Pan, Yu, Jianjun, Jia, Shidong, Scheinberg, Tahlia, Fitzpatrick, Michael, Bonnitcha, Paul, Sullivan, David R., Joshua, Anthony M., Azad, Arun A., Butler, Lisa M., Meikle, Peter J., and Horvath, Lisa G.

Published
2021
Full Text
View/download PDF

29. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Author

Azad, Arun A, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Ng, Siobhan, Pattison, David A, Ramdave, Shakher, Rana, Nisha, Redfern, Andrew D, Rutherford, Natalie K, Sandhu, Shahneen, Scott, Andrew M, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Violet, John A, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, Zhang, Alison Y, Kwan, Edmond M, and Macdonald, William

Published
2021
Full Text
View/download PDF

30. Merkel Cell Carcinoma

Author

Covelli, Andrea M., Joshua, Anthony M., Lipa, Joan E., Butler, Marcus O., Snell, Laura, Sun, Alexander, Wright, Frances C., Wright, Frances C., editor, Escallon, Jaime M., editor, Cukier, Moises, editor, Tsang, Melanie E., editor, and Hameed, Usmaan, editor

Published
2020
Full Text
View/download PDF

31. Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT.

Author

Li, Sherrington, Nguyen, Andrew, Counter, William, John, Nikeith C., De Leon, Jeremiah, Hruby, George, Joshua, Anthony M., Stricker, Phillip, Crumbaker, Megan, Ayati, Narjess, Chan, Lyn, Sabahi, Zahra, Swiha, Mina, Kneebone, Andrew, Wong, Keith, Liu, Victor, Sharma, Shikha, Agrawal, Shikha, and Emmett, Louise M.

Published
2024
Full Text
View/download PDF

33. First-line avelumab plus chemotherapy in patients with advanced solid tumors: results from the phase 1b/2 JAVELIN Chemotherapy Medley study

Author

Wheatley, Duncan A., primary, Berardi, Rossana, additional, Climent Duran, Miguel A., additional, Tomiak, Anna, additional, Greystoke, Alastair P., additional, Joshua, Anthony M., additional, Arkenau, Hendrik-Tobias, additional, Géczi, Lajos, additional, Garcia-Corbacho, Javier, additional, Paz-Ares, Luis G., additional, Hussain, Syed A., additional, Petruželka, Lubos, additional, Delmonte, Angelo, additional, Chappey, Colombe, additional, Masters, Joanna C., additional, Michelon, Elisabete, additional, Murphy, Danielle A., additional, Mwewa, Sandrine, additional, Cesari, Rossano, additional, and Doger de Speville, Bernard, additional

Published
2024
Full Text
View/download PDF

35. Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

Author

Daud, Adil I, Wolchok, Jedd D, Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S, Ribas, Antoni, Hodi, F Stephen, Joshua, Anthony M, Kefford, Richard, Hersey, Peter, Joseph, Richard, Gangadhar, Tara C, Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K, Li, Xiaoyun Nicole, Emancipator, Kenneth, Dolled-Filhart, Marisa, Kang, S Peter, Ebbinghaus, Scot, and Hamid, Omid

Subjects
Cancer, Brain Disorders, Clinical Research, Clinical Trials and Supportive Activities, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, B7-H1 Antigen, Biomarkers, Tumor, Drug Administration Schedule, Female, Humans, Immunohistochemistry, Male, Melanoma, Middle Aged, Neoplasm Staging, Programmed Cell Death 1 Receptor, Survival Rate, Treatment Outcome, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks. Tumor response was assessed every 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review. Primary outcome was objective response rate. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Membranous PD-L1 expression in tumor and tumor-associated immune cells was assessed by a clinical trial immunohistochemistry assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clinical outcome; a score ≥ 2 (membranous staining in ≥ 1% of cells) was considered positive. Results Of 451 patients with evaluable PD-L1 expression, 344 (76%) had PD-L1-positive tumors. Demographic and staging variables were equally distributed among PD-L1-positive and -negative patients. An association between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95% CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95% CI, 0.69 to 0.83) was observed ( P < .001 for each). Objective response rate was 8%, 12%, 22%, 43%, 57%, and 53% for MEL 0, 1, 2, 3, 4, and 5, respectively. Conclusion PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.

Published
2016

36. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

Author

Hodi, F Stephen, Hwu, Wen-Jen, Kefford, Richard, Weber, Jeffrey S, Daud, Adil, Hamid, Omid, Patnaik, Amita, Ribas, Antoni, Robert, Caroline, Gangadhar, Tara C, Joshua, Anthony M, Hersey, Peter, Dronca, Roxana, Joseph, Richard, Hille, Darcy, Xue, Dahai, Li, Xiaoyun Nicole, Kang, S Peter, Ebbinghaus, Scot, Perrone, Andrea, and Wolchok, Jedd D

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Good Health and Well Being, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Female, Humans, Melanoma, Middle Aged, Response Evaluation Criteria in Solid Tumors, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeWe evaluated atypical response patterns and the relationship between overall survival and best overall response measured per immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) in patients with advanced melanoma treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827).Patients and methodsPatients received pembrolizumab 2 or 10 mg/kg every 2 weeks or every 3 weeks. Atypical responses were identified by using centrally assessed irRC data in patients with ≥ 28 weeks of imaging. Pseudoprogression was defined as ≥ 25% increase in tumor burden at week 12 (early) or any assessment after week 12 (delayed) that was not confirmed as progressive disease at next assessment. Response was assessed centrally per irRC and RECIST v1.1.ResultsOf the 655 patients with melanoma enrolled, 327 had ≥ 28 weeks of imaging follow-up. Twenty-four (7%) of these 327 patients had atypical responses (15 [5%] with early pseudoprogression and nine [3%] with delayed pseudoprogression). Of the 592 patients who survived ≥ 12 weeks, 84 (14%) experienced progressive disease per RECIST v1.1 but nonprogressive disease per irRC. Two-year overall survival rates were 77.6% in patients with nonprogressive disease per both criteria (n = 331), 37.5% in patients with progressive disease per RECIST v1.1 but nonprogressive disease per irRC (n = 84), and 17.3% in patients with progressive disease per both criteria (n = 177).ConclusionAtypical responses were observed in patients with melanoma treated with pembrolizumab. Based on survival analysis, conventional RECIST might underestimate the benefit of pembrolizumab in approximately 15% of patients; modified criteria that permit treatment beyond initial progression per RECIST v1.1 might prevent premature cessation of treatment.

Published
2016

37. Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis

Author

Wu, Sunny Z., Roden, Daniel L., Al-Eryani, Ghamdan, Bartonicek, Nenad, Harvey, Kate, Cazet, Aurélie S., Chan, Chia-Ling, Junankar, Simon, Hui, Mun N., Millar, Ewan A., Beretov, Julia, Horvath, Lisa, Joshua, Anthony M., Stricker, Phillip, Wilmott, James S., Quek, Camelia, Long, Georgina V., Scolyer, Richard A., Yeung, Bertrand Z., Segara, Davendra, Mak, Cindy, Warrier, Sanjay, Powell, Joseph E., O’Toole, Sandra, Lim, Elgene, and Swarbrick, Alexander

Published
2021
Full Text
View/download PDF

38. A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205

Author

Hotte, Sebastien J., Chi, Kim N., Joshua, Anthony M., Tu, Donsheng, Macfarlane, Robyn J., Gregg, Rirchard W., Ruether, Joseph D., Basappa, Naveen S., Finch, Daygen, Salim, Muhammad, Winquist, Eric W., Torri, Vamsee, North, Scott, Kollmannsberger, Christian, Ellard, Susan L., Eigl, Bernard J., Tinker, Anna, Allan, Alison L., Beja, Kevin, Annala, Matti, Powers, Jean, Wyatt, Alexander W., and Seymour, Lesley

Published
2019
Full Text
View/download PDF

39. Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

Author

Emmett, Louise, Crumbaker, Megan, Ho, Bao, Willowson, Kathy, Eu, Peter, Ratnayake, Lalith, Epstein, Richard, Blanksby, Ashley, Horvath, Lisa, Guminski, Alex, Mahon, Kate, Gedye, Craig, Yin, Charlotte, Stricker, Phillip, and Joshua, Anthony M.

Published
2019
Full Text
View/download PDF

40. Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.

Author

Pinato, David James, primary, Jones, Robert Hugh, additional, Forster, Martin D., additional, Joshua, Anthony M., additional, Korolewicz, James, additional, Benafif, Sarah, additional, Aboud, Karam, additional, Liu, Jia (Jenny), additional, Cosman, Rasha, additional, Paull, Jeremy, additional, Fairley, Jacinth, additional, Edmondson, Stephanie Ruth, additional, and Spicer, James F., additional

Published
2024
Full Text
View/download PDF

41. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Author

Beer, Tomasz M, Armstrong, Andrew J, Rathkopf, Dana E, Loriot, Yohann, Sternberg, Cora N, Higano, Celestia S, Iversen, Peter, Bhattacharya, Suman, Carles, Joan, Chowdhury, Simon, Davis, Ian D, de Bono, Johann S, Evans, Christopher P, Fizazi, Karim, Joshua, Anthony M, Kim, Choung-Soo, Kimura, Go, Mainwaring, Paul, Mansbach, Harry, Miller, Kurt, Noonberg, Sarah B, Perabo, Frank, Phung, De, Saad, Fred, Scher, Howard I, Taplin, Mary-Ellen, Venner, Peter M, and Tombal, Bertrand

Subjects
Urologic Diseases, Clinical Trials and Supportive Activities, Prostate Cancer, Clinical Research, Aging, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adenocarcinoma, Administration, Oral, Androgen Receptor Antagonists, Antineoplastic Agents, Hormonal, Benzamides, Disease Progression, Double-Blind Method, Humans, Male, Neoplasm Metastasis, Nitriles, Phenylthiohydantoin, Prostatic Neoplasms, Radiography, Receptors, Androgen, Survival Analysis, PREVAIL Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundEnzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.MethodsIn this double-blind, phase 3 study, we randomly assigned 1717 patients to receive either enzalutamide (at a dose of 160 mg) or placebo once daily. The coprimary end points were radiographic progression-free survival and overall survival.ResultsThe study was stopped after a planned interim analysis, conducted when 540 deaths had been reported, showed a benefit of the active treatment. The rate of radiographic progression-free survival at 12 months was 65% among patients treated with enzalutamide, as compared with 14% among patients receiving placebo (81% risk reduction; hazard ratio in the enzalutamide group, 0.19; 95% confidence interval [CI], 0.15 to 0.23; P

Published
2014

43. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

Author

Tio, Martin, Rai, Rajat, Ezeoke, Ogochukwu M., McQuade, Jennifer L., Zimmer, Lisa, Khoo, Chloe, Park, John J., Spain, Lavinia, Turajlic, Samra, Ardolino, Luke, Yip, Desmond, Goldinger, Simone M., Cohen, Justine V., Millward, Michael, Atkinson, Victoria, Kane, Alisa Y., Ascierto, Paolo A., Garbe, Claus, Gutzmer, Ralf, Johnson, Douglas B., Rizvi, Hira A., Joshua, Anthony M., Hellmann, Matthew D., Long, Georgina V., and Menzies, Alexander M.

Published
2018
Full Text
View/download PDF

44. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer

Author

Francini, Edoardo, Yip, Steven, Ahmed, Shubidito, Li, Haocheng, Ardolino, Luke, Evan, Carolyn P., Kaymakcalan, Marina, Shaw, Grace K., Kantoff, Philip W., Taplin, Mary-Ellen, Alimohamed, Nimira S., Joshua, Anthony M., Heng, Daniel Y.C., and Sweeney, Christopher J.

Published
2018
Full Text
View/download PDF

45. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Author

Hamid, Omid, Robert, Caroline, Daud, Adil, Hodi, F Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D, Hersey, Peter, Joseph, Richard W, Weber, Jeffrey S, Dronca, Roxana, Gangadhar, Tara C, Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M, Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Tumeh, Paul C, Chmielowski, Bartosz, Ebbinghaus, Scot W, Li, Xiaoyun Nicole, Kang, S Peter, and Ribas, Antoni

Subjects
Humans, Melanoma, Brain Neoplasms, Skin Neoplasms, Antineoplastic Agents, Antibodies, Monoclonal, Drug Administration Schedule, Dose-Response Relationship, Drug, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Antibodies, Monoclonal, Humanized, Programmed Cell Death 1 Receptor, Human Genome, Genetics, Clinical Research, Patient Safety, Clinical Trials and Supportive Activities, Cancer, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundThe programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma.MethodsWe administered lambrolizumab intravenously at a dose of 10 mg per kilogram of body weight every 2 or 3 weeks or 2 mg per kilogram every 3 weeks in patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not. Tumor responses were assessed every 12 weeks.ResultsA total of 135 patients with advanced melanoma were treated. Common adverse events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were low grade. The confirmed response rate across all dose cohorts, evaluated by central radiologic review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was 38% (95% confidence interval [CI], 25 to 44), with the highest confirmed response rate observed in the cohort that received 10 mg per kilogram every 2 weeks (52%; 95% CI, 38 to 66). The response rate did not differ significantly between patients who had received prior ipilimumab treatment and those who had not (confirmed response rate, 38% [95% CI, 23 to 55] and 37% [95% CI, 26 to 49], respectively). Responses were durable in the majority of patients (median follow-up, 11 months among patients who had a response); 81% of the patients who had a response (42 of 52) were still receiving treatment at the time of analysis in March 2013. The overall median progression-free survival among the 135 patients was longer than 7 months.ConclusionsIn patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. (Funded by Merck Sharp and Dohme; ClinicalTrials.gov number, NCT01295827.).

Published
2013

48. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2

Author

Nguyen, Linh T., Saibil, Samuel D., Sotov, Valentin, Le, Michael X., Khoja, Leila, Ghazarian, Danny, Bonilla, Luisa, Majeed, Habeeb, Hogg, David, Joshua, Anthony M., Crump, Michael, Franke, Norman, Spreafico, Anna, Hansen, Aaron, Al-Habeeb, Ayman, Leong, Wey, Easson, Alexandra, Reedijk, Michael, Goldstein, David P., McCready, David, Yasufuku, Kazuhiro, Waddell, Thomas, Cypel, Marcelo, Pierre, Andrew, Zhang, Bianzheng, Boross-Harmer, Sarah, Cipollone, Jane, Nelles, Megan, Scheid, Elizabeth, Fyrsta, Michael, Lo, Charlotte S., Nie, Jessica, Yam, Jennifer Y., Yen, Pei Hua, Gray, Diana, Motta, Vinicius, Elford, Alisha R., DeLuca, Stephanie, Wang, Lisa, Effendi, Stephanie, Ellenchery, Ragitha, Hirano, Naoto, Ohashi, Pamela S., and Butler, Marcus O.

Published
2019
Full Text
View/download PDF

49. Data from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Author

Fleshner, Neil E., primary, Sayyid, Rashid K., primary, Hansen, Aaron R., primary, Chin, Joseph L.K., primary, Fernandes, Ricardo, primary, Winquist, Eric, primary, van der Kwast, Theodorus, primary, Sweet, Joan, primary, Lajkosz, Katherine, primary, Kenk, Miran, primary, Hersey, Karen, primary, Veloso, Rosette, primary, Berlin, Doron, primary, Herrera-Caceres, Jaime O., primary, Sridhar, Srikala, primary, Moussa, Madeleine, primary, Finelli, Antonio, primary, Hamilton, Robert J., primary, Kulkarni, Girish S., primary, Zlotta, Alexandre R., primary, and Joshua, Anthony M., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Author

Fleshner, Neil E., primary, Sayyid, Rashid K., primary, Hansen, Aaron R., primary, Chin, Joseph L.K., primary, Fernandes, Ricardo, primary, Winquist, Eric, primary, van der Kwast, Theodorus, primary, Sweet, Joan, primary, Lajkosz, Katherine, primary, Kenk, Miran, primary, Hersey, Karen, primary, Veloso, Rosette, primary, Berlin, Doron, primary, Herrera-Caceres, Jaime O., primary, Sridhar, Srikala, primary, Moussa, Madeleine, primary, Finelli, Antonio, primary, Hamilton, Robert J., primary, Kulkarni, Girish S., primary, Zlotta, Alexandre R., primary, and Joshua, Anthony M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results